ACTA1

ACTA1 encodes skeletal muscle alpha-actin, the predominant thin-filament protein of adult skeletal muscle sarcomeres, where it polymerizes into filaments that interact with myosin to generate contractile force and with Z-line proteins such as alpha-actinin to organize the sarcomere (PMID:16945537, PMID:23029319). Its expression is developmentally regulated: alpha-cardiac actin predominates in fetal skeletal muscle and the heart, while ACTA1 becomes the exclusive skeletal isoform from infancy onward, accounting for the muscle-restricted phenotype of ACTA1 disease (PMID:16288873). Dominant disease-causing mutations act through a poison-protein mechanism rather than loss of function: mutant actin misfolds, polymerizes abnormally, and aggregates into insoluble filaments and nemaline/intranuclear rods (PMID:15198992), modifies the actin-actin interface to block strong myosin cross-bridge binding (PMID:23029319, PMID:27112274), and in some cases stabilizes tropomyosin in the switched-off state without disrupting sarcomere ultrastructure (PMID:17387733). Disease severity tracks directly with mutant protein load, and raising the wild-type-to-mutant ratio—including by substituting cardiac alpha-actin—is therapeutic in mouse models (PMID:21303860, PMID:23736297). Beyond contraction, ACTA1 deficiency is associated with mislocalization of nuclear envelope and LINC-complex proteins and abnormal nuclear shape in patient muscle (PMID:35810298).

1. 2004 High

   Established that ACTA1 missense mutations act dominant-negatively at the protein level rather than through haploinsufficiency, by showing mutant actin misfolds and is incorporated into insoluble filaments.

   Evidence Mutant actin-EGFP transfection of C2C12 myoblasts plus isoelectric focusing and solubility fractionation of patient muscle

   PMID:15198992

   Open questions at the time

   • Did not quantify how mutant load relates to severity
   • Did not resolve which specific binding interfaces are disrupted
2. 2005 Medium

   Explained the muscle-restricted, heart-sparing phenotype of ACTA1 disease by mapping the developmental switch from cardiac to skeletal alpha-actin isoforms.

   Evidence Quantitative protein expression analysis of human heart and skeletal muscle across developmental stages

   PMID:16288873

   Open questions at the time

   • Single-lab quantification
   • Does not establish functional interchangeability of the isoforms
3. 2006 Medium

   Defined a concrete biochemical lesion by showing a mutation slows actin motility and weakens binding to the Z-line protein alpha-actinin.

   Evidence In vitro motility assay and alpha-actinin binding affinity on actin from a single patient biopsy

   PMID:16945537

   Open questions at the time

   • Single patient sample
   • Modest motility effect of unclear clinical weight
4. 2006 Low

   Offered a structural rationale for intranuclear rod myopathy by placing a recurrent mutated residue adjacent to actin's nuclear export signal.

   Evidence Mutation sequencing and structural modeling of NES proximity, linked to nuclear accumulation seen in C2C12 transfection

   PMID:16427282

   Open questions at the time

   • Modeling only, no direct test of NES disruption
   • No measurement of altered nuclear export kinetics
5. 2007 High

   Distinguished a functional disease class from structural nemaline myopathy by showing some mutations weaken muscle by stabilizing tropomyosin off-state without sarcomere disorganization.

   Evidence In vitro motility, mass spectrometry, 2D gels, electron microscopy and C2C12 expression of CFTD mutants

   PMID:17387733

   Open questions at the time

   • Mechanism of tropomyosin stabilization not resolved at atomic level
   • Genotype-phenotype generality across mutations untested
6. 2011 High

   Demonstrated that mutant ACTA1 protein dose, not mere presence, determines severity, by titrating mutant load via crosses with Acta1 knockouts.

   Evidence Transgenic D286G mouse models, mass-spectrometry quantification, muscle mechanics and histopathology

   PMID:21303860

   Open questions at the time

   • Does not pinpoint the molecular step disrupted by excess mutant actin
   • Single mutation tested
7. 2012 Medium

   Provided a mechanistic basis for force loss by showing the mutation alters the actin-actin interface to prevent strong myosin binding.

   Evidence Single permeabilized fiber mechanics from transgenic mice with molecular energy-state computation

   PMID:23029319

   Open questions at the time

   • Interface modification inferred computationally
   • Single lab and single mutation
8. 2013 High

   Established a therapeutic principle by rescuing lethality through cardiac alpha-actin substitution, raising the wild-type-to-mutant ratio.

   Evidence Transgenic mouse crosses over-expressing cardiac alpha-actin with survival analysis and histopathology

   PMID:23736297

   Open questions at the time

   • Functional substitution incomplete (residual lethality)
   • Translation to human therapy untested
9. 2013 Medium

   Linked an ACTA1 mutation to altered cross-bridge cycling and energy cost in vivo, beyond static force deficits.

   Evidence In vivo force measurement, 31P-MRS and MRI in the H40Y mouse model

   PMID:23613869

   Open questions at the time

   • Mitochondrial vs actomyosin origin of energy cost unresolved
   • Single mutation model
10. 2016 Medium

    Resolved how a specific mutation corrupts filament biophysics by disrupting the DNase-I-binding loop and forming abnormally stiff homopolymers that block myosin binding.

    Evidence Molecular dynamics simulation with filament mechanics, DNase I binding and in vitro motility assays

    PMID:27112274

    Open questions at the time

    • Computational structural claims need experimental structures
    • Generalizability to other mutations unknown
11. 2022 Medium

    Extended ACTA1 function beyond contraction by linking deficiency to nuclear envelope/LINC-complex mislocalization and abnormal nuclear shape.

    Evidence Immunofluorescence of lamin A/C, Nesprin-1/2 and electron microscopy in patient muscle biopsies

    PMID:35810298

    Open questions at the time

    • Correlative patient-tissue data, not mechanistic
    • Direct interaction between alpha-actin and LINC components not demonstrated

• How distinct mutation classes map onto the spectrum of clinical phenotypes, and whether the nuclear/LINC defect is a primary mechanism or downstream consequence, remains unresolved.
• No unifying structural model linking interface mutations to phenotype severity
• Causal role of LINC disruption in pathology untested
• No human therapeutic validation of ratio-shifting strategy